NASDAQ : KTTA
Pasithea Therapeutics Corp. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.3696 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.35M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 12.37M |
| Enterprise Value | -33.29M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 33.41M |
| Shares Outstanding | 33.41M |
| Shares Change (YoY) | +654.51% |
| Shares Change (QoQ) | +31.89% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 27.66% |
| Float | 19.68M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 26.25 |
| Quick Ratio | 24.85 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -65.49% |
| Return on Assets (ROA) | -36.00% |
| Return on Invested Capital (ROIC) | -38.05% |
| Return on Capital Employed (ROCE) | -39.69% |
| Weighted Average Cost of Capital (WACC) | 6.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.26M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -48.83% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.63 |
| Relative Strength Index (RSI) | 34.19 |
| Average Volume (20 Days) | 322,192 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 174,598 |
| Short Previous Month | 159,831 |
| Short % of Shares Out | 0.52% |
| Short % of Float | 0.89% |
| Short Ratio (days to cover) | 1.24 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.79M |
| Pretax Income | -21.29M |
| Net Income | -21.29M |
| EBITDA | -19.14M |
| EBIT | -19.79M |
| Earnings Per Share (EPS) | -$1.11 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 45.66M |
| Total Debt | n/a |
| Net Cash | 45.66M |
| Net Cash Per Share | $1.37 |
| Equity (Book Value) | 49.84M |
| Book Value Per Share | 1.49 |
| Working Capital | 46.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -17.78M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 654,215 |
| Net Borrowing | n/a |
| Free Cash Flow | -17.78M |
| FCF Per Share | -$0.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -654.51% |
| Shareholder Yield | -654.51% |
| Earnings Yield | -299.81% |
| FCF Yield | -143.75% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 2, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |